Openbookopenbook
Equity
LKFT
+0.0 · +0.00%
USD · NASDAQ

Lakefront Biotherapeutics NV(LKFT) Stock Analysis | Healthcare

USD --+0.00%
Reward62Moderate
Risk18Low
75%Data
Strong 60% profit margin · Revenue down 82% YoY
Quality Compounder
Market Cap:1.89Bn
ⓘ
Reward Rating
62
Moderate
Reward Assessment
75% data coverage
Top 50% of stocksView factors
ⓘ
Risk Rating
18
Low
Risk Assessment
2 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on LKFT to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for LKFT, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $23.70.

What is Lakefront Biotherapeutics NV?

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.

LKFT · Verdict

Solid reward · low risk

LKFT stands out on volatility and balance sheet, but watch the cash flow signal.

Based on 88% data coverage

LKFT · Verdict

What’s working & what to watch

Strengths 4

  • Volatility95/100

    Top decile vs peers

  • Balance sheet92/100

    Interest covered 136.7×

  • Profitability76/100

    29% net margin · 20% ROE

  • Growth65/100

    Revenue +66.4% CAGR

Watchouts 1

  • Cash flow42/100

    -24% free-cash-flow margin

Model-based scoring. For information only — not financial advice.

What is Lakefront Biotherapeutics NV?

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.89B, and a P/E ratio of 2.7x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (62)

The scoring profile indicates moderate reward potential, with profitability and growth as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

KARDSmall Cap / 1.9B market cap
Kardigan, Inc. Common Stock
Compare
IMCRSmall Cap / 1.9B market cap
Immunocore Holdings Ltd
Compare
BRVESmall Cap / 1.9B market cap
Braveheart Bio, Inc. Common Stock
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap1.89B
P/E Ratio2.7426
Dividend YieldN/A
Beta0.112
Insider Activity
12M windowNo data
No insider activity data available for this ticker.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.